Complement factor i promotes progression of cutaneous squamous cell carcinoma

Journal of Investigative Dermatology

Volumn 135, Issue 2, 2015, Pages 579-588

  Riihilä, Pilvi ^a,b   Nissinen, Liisa ^a,b   Farshchian, Mehdi ^a,b   Kivisaari, Atte ^a,b   Ala aho, Risto ^a,b   Kallajoki, Markku ^a   Grénman, Reidar ^a   Meri, Seppo ^c   Peltonen, Sirkku ^a   Peltonen, Juha ^d   Kähäri, Veli Matti ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR I; GAMMA INTERFERON; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; EPIDERMOLYSIS BULLOSA DYSTROPHICA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEBORRHEIC KERATOSIS; SKIN CARCINOMA; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING; ADULT; AGED; ANIMAL; CELL MOTION; DISEASE COURSE; FEMALE; MIDDLE AGED; MOUSE; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COMPLEMENT FACTOR I; DISEASE PROGRESSION; FEMALE; GENES, RAS; HUMANS; MICE; MICE, SCID; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84925369338     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.376     Document Type: Article

References (40)

1. Ala-aho R, Ahonen M, George SJ et al. (2004) Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene 23:5111-23
2. Boukamp P, Petrussevska RT, Breitkreutz D et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-71
3. Boukamp P, Stanbridge EJ, Foo DY et al. (1990) c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 50:2840-7
4. Dovezenski N, Billetta R, Gigli I (1992) Expression and localization of proteins of the complement system in human skin. J Clin Invest 90:2000-12
5. Farshchian M, Kivisaari A, Ala-aho R et al. (2011) Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 179:1110-9
6. Gasque P, Julen N, Ischenko AM et al. (1992) Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 149:1381-7
7. Goldberger G, Arnaout MA, Aden D et al. (1984) Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J Biol Chem 259:6492-7
8. Gorter A, Meri S (1999) Immune evasion of tumor cells using membranebound complement regulatory proteins. Immunol Today 20:576-82
9. Julen N, Dauchel H, Lemercier C et al. (1992) In vitro biosynthesis of complement factor I by human endothelial cells. Eur J Immunol 22:213-7
10. Junttila MR, Ala-Aho R, Jokilehto T et al. (2007) p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26:5267-79
11. Kivisaari A, Kähäri VM (2013) Squamous cell carcinoma of the skin: emerging need for novel biomarkers. World J Clin Oncol 4:85-90
12. Kivisaari AK, Kallajoki M, Mirtti T et al. (2008) Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas. Br J Dermatol 158:778-85
13. Kivisaari AK, Kallajoki M, Ala-aho R et al. (2010) Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol 163:726-35
14. Kononen J, Bubendorf L, Kallioniemi A et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-7
15. Legoedec J, Gasque P, Jeanne JF et al. (1995) Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 25:3460-6
16. Leivonen S-K, Ala-aho R, Koli K et al. (2006) Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells. Oncogene 25:2588-600
17. Mueller MM, Peter W, Mappes M et al. (2001) Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 159:1567-79
18. Nagasawa S, Stroud RM (1977) Mechanism of action of the C3b inactivator: requirement for a high molecular weight cofactor (C3b-C4bINA cofactor) and production of a new C3b derivative (C3b'). Immunochemistry 14:749-56
19. Nilsson SC, Sim RB, Lea SM et al. (2011) Complement factor I in health and disease. Mol Immunol 48:1611-20
20. Okroj M, Hsu YF, Ajona D et al. (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45:169-79
21. Ratushny V, Gober MD, Hick R et al. (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122:464-72
22. Reca R, Cramer D, Yan J et al. (2007) A novel role of complement in mobilization: immunodeficient mice are poor granulocyte-colony stimulating factor mobilizers because they lack complement-activating immunoglobulins. Stem Cells 25:3093-100
23. Ricklin D, Hajishengallis G, Yang K et al. (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785-97
24. Riihilä PM, Nissinen LM, Ala-aho R et al. (2014) Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol 134:498-506
25. Robinson MD, McCarthy DJ, Smyth GK et al. (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139-40
26. Rogers HW, Weinstock MA, Harris AR et al. (2010) Incidence estimate of nonmelanoma skin cancer in the United States. Arch Dermatol 146:283-7
27. Rutkowski MJ, Sughrue ME, Kane AJ et al. (2010a) The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res 59:897-905
28. Rutkowski MJ, Sughrue ME, Kane AJ et al. (2010b) Cancer and the complement cascade. Mol Cancer Res 8:1453-65
29. Schlaf G, Demberg T, Beisel N et al. (2001) Expression and regulation of complement factors H and I in rat and human cells: some critical notes. Mol Immunol 38:231-9
30. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-5
31. Schulze M, Pruchno CJ, Burns M et al. (1993) Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 142:179-87
32. Stokes A, Joutsa J, Ala-aho R et al. (2010) Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 16:2022-35
33. Timar KK, Dallos A, Kiss M et al. (2007a) Expression of terminal complement components by human keratinocytes. Mol Immunol 44:2578-86
34. Timar KK, Junnikkala S, Dallos A et al. (2007b) Human keratinocytes produce the complement inhibitor factor I: synthesis is regulated by interferongamma. Mol Immunol 44:2943-9
35. Tufaro AP, Chuang JC, Prasad N et al. (2011) Molecular markers in cutaneous squamous cell carcinoma. Int J Surg Oncol 2011:231475
36. Vetvicka V, Reed W, Hoover ML et al. (1993) Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3. J Immunol 150:4052-60
37. Vyse TJ, Morley BJ, Bartok I et al. (1996) The molecular basis of hereditary complement factor I deficiency. J Clin Invest 97:925-33
38. Watt SA, Pourreyron C, Purdie K et al. (2011) Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene 30:4666-77
39. Whaley K (1980) Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med 151:501-16
40. Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729-40